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promise for gene delivery to the nervous system. However,
vector toxicity and transgene silencing have created signiﬁ-
cant barriers to vector applications to the brain. Recently,
we described a vector defective for all immediate-early gene
expression and deleted for the joint region between the two
unique genome segments that proved capable of extended
transgene expression in non-neuronal cells. Sustained expres-
sion required the proximity of boundary elements from the
latency locus. As conﬁrmed here, we have also found that a
transgene cassette introduced into the ICP4 locus is highly
active in neurons but silent in primary ﬁbroblasts. Remarkably,
we observed that removal of the virion host shutoff (vhs) gene
further improved transgene expression in neurons without
inducing expression of viral genes. In rat hippocampus, the
vhs-deleted vector showed robust transgene expression exclu-
sively in neurons for at least 1 month without evidence of
toxicity or inﬂammation. This HSV vector design holds prom-
ise for gene delivery to the brain, including durable expression
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Replication-defective herpes simplex virus (HSV)-based vectors have
the potential to provide an invaluable tool to both studies of brain func-
tion and treatment of CNS disorders. HSV genomes persisting in neu-
rons do not integrate and can serve as a platform for therapeutic gene
expression. Replication-defective HSV vectors have been tested for
gene therapy approaches in the CNS1–3 and peripheral nervous
system.4–7 However, CNS applications have been plagued by residual
neuronal toxicity and progressive loss of transgene expression.8–10
Viral toxicity results from expression of the viral immediate early
(IE) protein ICP0, a protein with functions related to viral chromatin
modiﬁcation and resistance to innate anti-viral responses.11 In the
absence of ICP0, rapid genome silencing ensues, resulting in low trans-
gene expression, while, in the presence of ICP0, signiﬁcant toxicity
results in loss of neuronal cell function and viability.Molecular Therapy:
This is an open access article under the CC BY-NCIn sensory neurons, ICP0 fails to accumulate in the nucleus,12 and
ICP0-mediated cytotoxicity is further avoided by silencing of the viral
genome and the establishment of latency. The viral latency-associated
transcript (LAT) locus remains transcriptionally active during la-
tency, and the LAT promoter elements have been used to express
transgenes in sensory neurons.4,5,13,14 However, expression was typi-
cally short-term or low,4,15 and promoter activity was not seen in all
latently infected neurons.16 We have recently reported that, in the
absence of IE gene activity, transgene expression from a non-viral
promoter can be maintained in non-neuronal cells when the expres-
sion cassette is placed between two clusters of CTCF binding motifs
referred to as CTRL1 and CTRL217 ﬂanking the LAT promoter.18
This arrangement remained active when relocated to different inter-
genic regions unrelated to the latency locus. Interestingly, primary
neurons isolated from fetal rat dorsal root ganglia (rDRG) also dis-
played expression of a second reporter cassette located in the deleted
ICP4 locus. This ﬁnding prompted further examination of the ability
of the ICP4 locus to support transgene expression in neurons in the
brain.
Preliminary observations in our lab suggested that elimination of the
virion host shut-off function (vhs) may further reduce the already
minimal toxicity of IE gene-depleted vectors. Vhs functions as a viru-
lence factor that reduces immune recognition of infected cells in vivo
and helps evade the innate anti-viral interferon (IFN) responses;19–21
vhs-deﬁcient viruses are attenuated for neurovirulence. Since vhs is an
mRNA-speciﬁc RNase, we reasoned that it could potentially reduce
transgene mRNA and corresponding protein expression. Thus weMethods & Clinical Development Vol. 6 September 2017 ª 2017 79
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Structure and Analysis of the JDNI8 Vector
(A) Genomic structure of KOS-37 BAC and the derivative
JDNI5 and JDNI8 vectors loxP-flanked (BAC regions be-
tween UL37 and UL38 not shown). UL, unique long
segment; US, unique short segment. The terminal and in-
ternal inverted repeats are represented by open boxes.
Deletions in JDNI518 and JDNI8 are indicated by black
boxes (D). Both vectors contain the entry-enhancing N/T
mutations in the gB gene (gB:NT)45 and a ubiquitin C
promoter (UbCp)-mCherry cassette in the ICP4 locus; the
SV40 poly(A) region of the mCherry cassette is repre-
sented by a small patterned box. The cross-hatched
horizontal box (bICP22) indicates conversion of the
ICP22 IE gene to early-expression kinetics by promoter
TAATGARAT deletion. (B) Growth curves of JDNI5 and
JDNI8 in complementing cells. U2OS-ICP4/27 cells were
infected with JDNI5 and JDNI8 vectors at 1 gc/cell, and
supernatant virus titers were determined in gc per milliliter
every day for 5 days (averages of duplicate wells). (C)
Relative nuclear viral DNA levels at 2 hr post-infection of
HDFs with 5,000 gc of JDNI5 and JDNI8. Viral gc numbers
were determined by qPCR for the gD gene normalized to
the cellular 18S rRNA gene content (averages of duplicate
wells). (D) mCherry protein and (E) mRNA expression in
vector-infected HDFs without and with ICP0 comple-
mentation. Cells were infected at 25,000 gc/cell with
JDNI5DB or JDNI8DB and superinfected 6 days later with
mock or QOZHG vector (108 gc/well). One day later, mi-
croscopy fields were imaged for mCherry fluorescence,
DAPI-stained nuclei, and bright field. Separately, mRNA
was collected 1 day after superinfection, and mCherry
mRNA levels in duplicate samples were measured in trip-
licate, averaged, and normalized to viral gc in the same
samples. Normalized values ±SD are presented relative to
JDNI5DB infected cells at 7 dpi.
Molecular Therapy: Methods & Clinical Developmentdeleted the vhs (UL41) gene from our most recent vector, JDNI5,
18
generating a new backbone that was named JDNI8, and compared
the 2 vectors for transgene expression from the deleted ICP4 locus
in rat brain.
The results of our analyses show that the human ubiquitin C (UbC)
promoter placed between the end points of the ICP4 gene deletion al-
lows expression of the linked reporter gene in vivo in rat hippocampal
neurons. Furthermore, expression was enhanced by deletion of the
vhs gene. No vector-associated toxicity was observed following rat
brain injections and expression persisted in neurons of the CNS for
at least 1 month, providing an effective platform for the delivery of
therapeutic transgenes to the CNS, including multiple transgenes or80 Molecular Therapy: Methods & Clinical Development Vol. 6 September 2017transgenes that are too large for accommodation
by other vector systems.
RESULTS
VectorConstruction andCharacterization in
Non-complementing Fibroblasts
JDNI8 was derived from JDNI5 by deletion of
the vhs locus (Figure 1A). JDNI5 and JDNI8grew at comparable rates on ICP4- and ICP27-complementing
U2OS cells [U2OS-ICP4/27]18 (Figure 1B), showing that vhs did
not clearly contribute to virus yield in cultured cells. Infection of
human dermal ﬁbroblasts (HDFs) with JDNI5 and JDNI8 at 5,000
genome copies (gc)/cell resulted in comparable levels of viral DNA
in the nuclei of infected cells at 2 hr post-infection (hpi) (Figure 1C),
indicating that deletion of vhs did not alter virus entry or transport of
viral DNA into the nucleus.
We previously demonstrated that removal of bacterial artiﬁcial chro-
mosome (BAC) sequences from BAC-based viral vectors reduces
vector toxicity for non-complementing cells.18 Cre recombination
was used to remove the bacterial sequences from JDNI5 and
Figure 2. JDNI5DB and JDNI8DB Transgene
Expression in HDFs and rDRGs
(A) mCherry transgene expression in rDRG cultures. Cells
were infected with 3,000 gc/cell of JDNI5DB (top) or
JDNI8DB (bottom). Bright-field (left) and mCherry fluo-
rescence images (right) were taken at 7 (left panels)
and 14 dpi (right panels). (B) mCherry mRNA levels in
JDNI5DB- and JDNI8DB-infected rDRGs at 7 and 14 dpi.
mCherry mRNA levels were normalized to viral gc in the
same samples, and the normalized values are presented
relative to JDNI5DB-infected cells at 7 dpi. (C) Cytotox-
icity for rDRGs in culture. Cells were infected with KOS,
JDNI5DB, or JDNI8DB virus at 3,000 gc/cell or mock-
infected, and cell viability was measured in triplicate
by MTT assay at 5 dpi. Plotted values represent the mean
ratios of virus-infected to mock-infected cells. (D)
Transgene and viral gene expression in HDFs (left) and
rDRGs (right). HDF and rDRG cultures were infected with
JDNI5DB or JDNI8DB vectors at 25,000 gc/cell or 3,000
gc/cell, respectively. At 7 dpi, mRNA levels of selected
genes were measured by qRT-PCR analysis. Data con-
version was performed using JDNI5 BAC DNA standard
curves generated with the same gene-specific primers
and normalization to viral gc in each sample. Values are
presented relative to JDNI5DB-infected HDF at 7 dpi.
Data in (B) and (D) represent averages ±SD of two inde-
pendent experiments.
www.moleculartherapy.orgJDNI8, creating JDNI5DB and JDNI8DB, respectively. Following
transduction of HDFs with JDNI5DB and JDNI8DB, neither vector
showed noticeable mCherry transgene expression at 7 dpi (Fig-
ure 1D), consistent with our previous results for JDNI5.18 The
presence of viral DNA in the nuclei of infected HDFs (Figure 1C)
with little corresponding protein expression suggested that both viral
genomes were epigenetically silenced. Restoration of the IE gene
ICP0 to ICP0-deﬁcient vectors has been shown to counteract epige-
netic repression.22,23 As anticipated, when JDNI5DB- and JDNI8DB-
infected HDFs were superinfected with QOZHG virus12 to supply
ICP0 expression, mCherry expression was restored (Figures 1D
and 1E). While the qRT-PCR data (Figure 1E) suggested that theMolecular Therapy: Methods & Clivhs deletion caused a decrease in mCherry
mRNA levels (6-fold), these levels were
extremely low compared to those in the pres-
ence of ICP0 (Figure 1E).
Characterization of Gene Expression in
Neuronal Cells
We previously reported that mCherry expres-
sion from JDNI5-based vectors was markedly
higher in rDRG neurons than in ﬁbroblasts
in vitro at 3 dpi. We therefore infected
rDRG cultures with JDNI5DB and JDNI8DB
to assess the effect of vhs deletion on trans-
gene expression in these cells. At 7 and 14
dpi, rDRGs infected with either virus showedabundant mCherry ﬂuorescence, but the signals were stronger in
JDNI8DB- than in JDNI5DB-infected cultures (Figures 2A and
S1). Analysis of reverse transcribed mRNA by qPCR revealed
that mCherry gene expression in JDNI8DB-infected rDRGs was
approximately 2.5- and 3-fold higher than in JDNI5DB-infected
rDRGs at 7 and 14 dpi, respectively (Figure 2B). To eliminate
the possibility that mCherry expression was affected by cytotox-
icity, we assessed cell viability after transduction of rDRGs with
JDNI5DB or JDNI8DB. No difference in cell viability was observed
between vector- and mock-infected cells, indicating that neither
vector displayed noticeable cytotoxicity (Figure 2C). Together,
these results showed that in neuronal cells, both JDNI5 andnical Development Vol. 6 September 2017 81
Figure 3. GFP Expression from JDNI7GFPDB and
JDNI8GFPDB in Infected HDFs and DRGs
(A) Schematic diagram of the genomic structure of
the JDNI8GFPDB vector derived from JDNI7GFP18
by deletion of the vhs (UL41) gene. Like JDNI7GFP,
JDNI8GFP contains a CAG promoter-eGFP expression
cassette in the LAT intron between an enhancer-like
LAT region (LAP2 or LATP2)4,46,47 and CTRL2. (B)
GFP fluorescence and (C) relative GFP mRNA levels
in JDNI7GFPDB- and JDNI8GFPDB-infected HDFs
(25,000 gc/cell) at 7 and 14 dpi. GFP qRT-PCR data
were normalized to viral gc in the same samples and are
presented as expression relative to that in JDNI7GFPDB
infected cells at 7 dpi. (D) GFP fluorescence and (E)
relative GFP mRNA levels in JDNI7GFPDB- and
JDNI8GFPDB-infected rDRGs (3,000 gc/cell) at 7 and
14 dpi. Data in (C) and (E) represent averages ±SD of
two independent experiments.
Molecular Therapy: Methods & Clinical DevelopmentJDNI8 can mediate prolonged transgene expression from the UbC
promoter at the ICP4 locus without apparent cytotoxicity and that
increased transgene expression correlates with the vhs gene deletion
in JDNI8.
To determine whether the vhs gene inﬂuences global viral gene
expression, we measured the mRNA levels of the mCherry transgene
and selected viral genes representing different kinetic classes and re-
gions of the viral genome in both HDFs and rDRGs (Figure 2D). In
HDFs, expression of most viral genes from JDNI5DB and JDNI8DB
was comparable, regardless of kinetic class or genomic location, indi-
cating that removal of vhs did not dramatically alter viral gene expres-
sion (Figure 2D, left side). In DRGs, expression of individual genes
was also similar between JDNI5DB and JDNI8DB, but with a few82 Molecular Therapy: Methods & Clinical Development Vol. 6 September 2017notable exceptions. mCherry expression per
genome copy was 50- to 100-fold higher than
in HDFs, considerably higher than expression
of any of the viral genes, and approximately
2-fold higher from JDNI8DB than from
JDNI5DB (Figure 2D, right side). Of interest,
the expression of ICP34.5 in DRGs, while
similar between the two vectors, was also
elevated compared to HDFs (25-fold for
JDNI8DB, 17-fold for JDNI5DB). The
ICP34.5 gene (g134.5) and the mCherry trans-
gene are both located in a terminal repeat,
relatively close to one another in the circular
genome. The kinetically modiﬁed promoter of
the ICP22 gene is also located in a terminal
repeat in our JDNI viruses and ICP22 was
expressed more abundantly than the majority
of viral genes in JDNI5DB-infected DRGs.
However, this was not seen in JDNI8DB-in-
fected DRGs. Together, these results indicated
that the vhs deletion caused selective upregula-tion of mCherry expression in a cell-restricted manner without
considerable changes in the global pattern of HSV gene expression.
Transgene Expression from the LAT Region in Neuronal and
Non-neuronal Cells
We recently reported that GFP transgene expression from the CAG
promoter (CMV immediate-early enhancer/chicken b-actin pro-
moter/chimeric intron) was maintained in non-neuronal cells when
the expression cassette was placed between two clusters of CTCF
binding motifs ﬂanking the LAT promoter in JDNI5; this vector
was referred to as JDNI7GFP.18 We deleted the vhs gene from
JDNI7GFP, creating JDNI8GFP (Figure 3A), to assess the effect on
GFP expression. HDFs and rDRGs were infected with BAC-deleted
(DB) JDNI7GFP or JDNI8GFP, GFP ﬂuorescence from infected cells
www.moleculartherapy.orgwas visualized at 7 and 14 dpi, and GFP mRNA levels were measured
in the same cells. In HDFs, GFP ﬂuorescence in JDNI7GFPDB-in-
fected cells was higher at both time points than in JDNI8GFPDB-in-
fected cells (Figure 3B), and mRNA levels were approximately 3-fold
higher in JDNI7GFPDB- than in JDNI8GFPDB-infected cells at both
7 and 14 dpi, decreasing by 25% (JDNI7GFPDB) and 35%
(JDNI8GFPDB) between the two time points (Figure 3C). In contrast,
GFP ﬂuorescence in rDRGs was higher at 7 and 14 days post-infection
with JDNI8GFPDB than with JDNI7GFPDB (Figure 3D), and GFP
mRNA abundance was 2.5-fold higher in JDNI8GFPDB- than
in JDNI7GFPDB-infected cultures at 7 dpi, although a difference
was no longer observed at 14 dpi (Figure 3E). While the increase in
GFP expression in rDRGs caused by the vhs deletion was thus tran-
sient compared to the increase in mCherry expression in rDRGs
noted earlier, these results indicated that the vhs deletion promoted
transgene expression in neuronal cells independent of the promoter
or location of the expression cassette within the viral genome. We
conﬁrmed that the disruption of the LAT locus and insertion of the
GFP cassette did not noticeably alter the effect of the vhs deletion
on mCherry expression (Figure S2). The reduced expression of GFP
observed in HDFs highlights the cell-type dependence of the effect
of vhs removal on transgene expression.
Analysis of the JDNI8DB Vector in Neurons In Vivo
To determine whether our vectors were capable of non-cytotoxic
transgene expression in neuronal cells in vivo, we injected JDNI5DB
and JDNI8DB into rat hippocampus. We used JDNI5R0DB, an ICP0-
rescued derivative of JDNI5 (Figure S3), as a positive control for
mCherry expression and vector-associated toxicity. At 7 days post-
vector administration, JDNI5DB showed relatively low mCherry
expression and normal neuronal morphology (Figure 4B) that were
maintained at 1 month (Figure 4E). In comparison, more robust
mCherry expression was observed in JDNI5R0DB-injected animals
at 7 days (Figure 4A), but a signiﬁcant loss of mCherry signal
was observed after 1 month, and themorphology of the mCherry pos-
itive cells indicated substantial cytotoxicity (Figure 4D). JDNI8DB-
injected animals displayed enhanced mCherry expression in the
hippocampus at 7 days compared to JDNI5DB (Figure 4C), and
only a modest reduction in mCherry signal was apparent at 1 month
without overt change in cell morphology (Figure 4F); as opposed
to JDNI5R0DB-injected hippocampi, cells in JDNI8DB-injected
hippocampi maintained a clear neuronal morphology with many
dendritic and axonal elongations. We conﬁrmed that JDNI8DB trans-
gene expression was restricted to neurons by double-label immuno-
ﬂuorescence for mCherry and markers of neurons (NissI), astrocytes
(GFAP), and oligodendrocytes (O4) (Figure S4). Quantiﬁcation of
mCherry expression in the hippocampus (Figure 4G) demonstrated
that, in JDNI5DB-injected animals, only approximately 2% of the
pixels were mCherry positive at both time points, whereas some
12% were positive in JDNI8DB-injected animals at 7 days with
only a modest reduction to approximately 7% by 1 month. The
JDNI5R0DB injection yielded about 15% mCherry positive pixels at
7 days, but this fell to less than 2% by 1 month. Both the loss of
mCherry positive cells and the changes in cell morphology in theMolecular TJDNI5R0DB-injected animals were consistent with vector cytotox-
icity that was not observed in animals injected with either of the
ICP0-deﬁcient vectors.
To further assess toxicity in rat brain, Fluoro-Jade C staining was
performed on brain sections at 7 days post-vector administration.
Fluoro-Jade C stains degenerating neurons, regardless of the cause
of degeneration, and provides a clear indication of cytotoxicity. In
JDNI5R0DB-injected animals, many green, Fluoro-Jade C-positive
cells were observed, whereas no signal was detected in either
JDNI5DB- or JDNI8DB-injected animals (Figures 5A–5C). We also
examined the expression of CD45 as a marker for the accumulation
of inﬂammatory cells in the injected area. Many CD45 positive cells
accumulated near the mCherry positive cells in JDNI5R0DB-injected
animals, while only a few CD45 positive cells were observed in either
JDNI5DB- or JDNI8DB-injected animals (Figures 5D–5F). Similarly,
both caspase-3, an apoptotic marker (Figures 5G–5I), and NOS-2, an
inducible nitric oxide synthase involved in the immune response
(Figures 5J–5L), were induced by JDNI5R0DB injection, but not by
either JDNI5DB or JDNI8DB injection. Quantiﬁcation of these data
is shown in Figure 5M. Taken together, these observations conﬁrmed
that the presence of ICP0 results in neuronal cytotoxicity and
apoptosis in the hippocampus, along with activation of inﬂammatory
cell recruitment. Deletion of ICP0 reduced these negative conse-
quences although transgene expression was also reduced. Impor-
tantly, removal of the vhs gene from the ICP0-deﬁcient vector resulted
in enhanced transgene expression in the hippocampus without
toxicity.
DISCUSSION
HSV vectors offer the distinct advantage that they can accommodate
large payloads; for example, our current replication-defective back-
bones offer approximately 30 kb of usable space. This makes HSV
an ideal vector for gene therapy requiring the expression of large
or multiple transgenes. Given HSV’s ability to enter and establish
latency in sensory ganglia, current gene therapy studies using HSV
have focused on the peripheral nervous system, treating conditions
such as chronic pain and neuropathy.24 Establishing a platform for
replication-defective gene delivery to the CNS has been hampered
by problems including early silencing of CMV-promoter driven
transgenes and limited, low-level transgene expression from other
promoters such as the viral latency promoter.2,9 The level of transgene
expression is intricately tied to expression of the viral ICP0
protein: while ICP0 increases transgene expression, it also increases
cytotoxicity.25
We recently generated an ICP0-deﬁcient vector, JDNI5, that is
nontoxic and allowed transgene expression from an ectopic promoter
in multiple non-neuronal cell lines and rDRGs in vitro when the
transgene cassette was inserted between CTRLs associated with the
viral latency locus. Consistent with an overall silencing of expression
from the viral genome, a UbC-promoter-driven second transgene
present in the deleted ICP4 locus was not expressed in non-neuronal
cells. Surprisingly, however, it was expressed in DRGs. Thisherapy: Methods & Clinical Development Vol. 6 September 2017 83
Figure 4. Rat Hippocampal Transduction by
JDNI5R0DB, JDNI5DB, and JDNI8DB
2  109 gc of either vector was injected in the rat hippo-
campus, and DAPI (blue) and mCherry fluorescence (red)
were imaged at 7 days (A–C) or 1 month (D–F) after injection.
Upper images for each time point show a section of the in-
jected hippocampus; bottom images are enlargements of
the boxed areas. Scale bars in (A) and (D) upper panels (for all
upper panels), 500 mm; scale bars in (A) and (D) lower panels
(for all lower panels), 100 mm. (G) Quantification of mCherry
expression in the hippocampus of rats injected with
JDNI5R0DB (red), JDNI5DB (orange), or JDNI8DB (green) at
1 week (1w) or 1 month (1m) after vector inoculation. Data
are means ± SEM (n = three to five animals/group, five
sections/animal). *p < 0.05; **p < 0.01 (ANOVA and post hoc
Kruskal-Wallis test).
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Figure 5. Vector Toxicity in Rat Hippocampus
2  109 genome copies of JDNI5R0DB, JDNI5DB, or
JDNI8DB were injected into rat hippocampi, and brain
sections were collected and processed 7 days later. (A–C)
Fluoro-Jade C (FJC)-stained hippocampal sections from
JDNI-injected animals. Representative merged images of
FJC staining (green), DAPI staining (blue), and mCherry
fluorescence (red) are shown. (D–L) Immunohistochemical
staining of brain sections for CD45 (D–F), caspase-3 (G–I),
and NOS-2 (J–L) (all in green) is shown as merged images
with DAPI staining (blue) and mCherry fluorescence (red).
(M) Quantification of FJC, CD45, caspase-3, and NOS-2
in the hippocampus of rats 1 week after injection of
JDNI5R0DB, JDNI5DB, or JDNI8DB. Data are means ±
SEM (n = three to five animals/group, five sections/
animal). *p < 0.05; **p < 0.01 (ANOVA and post hoc
Kruskal-Wallis test).
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Molecular Therapy: Methods & Clinical Developmentobservation prompted our current efforts to examine the potential of
this vector and its vhs-deﬁcient counterpart, JDNI8, for CNS applica-
tions. The results indicated that both vectors are safe in the brain and
express their transgene at detectable levels from the ICP4 locus for at
least 1 month but also that JDNI8 provides the more robust expres-
sion proﬁle of the two.
Vhs plays a key role in attenuating the host anti-viral response by
mediating mRNA degradation and inhibiting host protein synthesis.
After virus entry into the cell through membrane fusion, vhs present
in the virion tegument is released into the cytoplasm where it causes
the shutoff of host protein synthesis. Available evidence suggests that
vhs-induced host shutoff action contributes to the regulation of viral
gene expression, in part by removing competition with cellular
mRNAs for translation factors and sharpening the transition between
the kinetic classes of viral genes, thereby supporting efﬁcient virus
replication during the lytic cycle.19–21 However, the functional signif-
icance of vhs in cell culture appears to vary between host cells. For
example, U2OS cells were reported to be permissive for replication
of viruses carrying a 588-nt deletion in the vhs gene26; these are the
parental cells used to generate the U2OS-ICP4/27 cells in which we
propagate our JDNI viruses, and indeed we observed little difference
in the growth rates of JDNI5 and JDNI8 in these cells (Figure 1B). In
other reports, a nonsense mutant of vhs, UL41NHB, showed a growth
delay in mouse embryonic ﬁbroblasts27 but grew normally in Vero
and C3H10T1/2 mouse embryo cells,28 while a vhs mutant that con-
tained a lacZ gene insertion in the vhs open reading frame (ORF) ex-
hibited a severe growth defect in human ﬁbrosarcomaHT1080 cells.29
It has further been shown that vhs enhances the accumulation of viral
late gene products in HeLa cells but is dispensable for late gene prod-
uct accumulation in Vero and other permissive cells.26 In a similar
vein, while treatment of human embryonic ﬁbroblasts with IFN-a
or -b signiﬁcantly inhibited plaque formation by a vhs-deﬁcient
mutant,30 IFN-a treatment did not reduce the plaquing efﬁciency
of a vhsmutant on Vero and U2OS cells.31 These observations clearly
showed that the role of vhs is variable between cell types and indicated
that vhs function is not critical in certain cell types. The host-cell-
dependent mechanism of vhs action is further supported by evidence
that primary sympathetic and sensory neuronal cultures are resistant
to vhs-mediated shut off of protein synthesis,32 an effect that could be
overcome by increasing the multiplicity of infection (MOI) and there-
fore the amount of vhs delivered to the cell during infection.21
The effect of vhs deletion has typically been assessed in vectors that still
retained expression of ICP0. The ICP0 protein globally stimulates
the expression of HSV genes, thereby enabling the production of viral
gene products thatmay act to compensate for vhs deﬁciency, including
ICP0 itself. ICP0 also has E3 ubiquitin ligase activity targeting the
degradation of host-cell proteins involved in the antiviral response,
some of which are also targets of vhs-mediated mRNA degrada-
tion.33,34 Thus, any effects of vhs disruption may be masked by effects
of ICP0. The vhs gene has been a favored target in replication-defective
HSV vectors for replacement or insertion of therapeutic transgene cas-
settes because vhs is dispensable in Vero cells typically used for HSV86 Molecular Therapy: Methods & Clinical Development Vol. 6 Septembgrowth.35 These vectors generally also expressed ICP0, potentially
obscuring any remaining effects of vhs disruption. Using a vector
that is deﬁcient in all IE gene activity, our study reveals an unexpected
consequence of deletion of the entire vhs ORF. While virus growth in
complementing U2OS-ICP4/27 cells, transduction efﬁciency of ﬁbro-
blasts, viral gene expression in ﬁbroblasts, and toxicity for sensory
neurons in culture and hippocampal neurons in vivo were largely un-
affected by the deletion, reporter gene expression from the UbC pro-
moter in a deleted ICP4 locus was speciﬁcally enhanced in neurons.
In vivo, expression persisted at an elevated level for at least 1 month.
Both the cellular promoter and genomic location are of interest when
considering our results. The UbC promoter has been tested for trans-
gene expression both in lentivirally transduced cultured neurons
in vitro and in transgenic mouse lines in vivo, revealing that it is
active and drives consistent levels of transgene expression in neuronal
cells.36,37 With respect to the location of the transgene in the HSV
genome, a recent report by Harkness et al. evaluating global HSV
genome expression in non-neuronal MRC5 cells and trigeminal gan-
glion (TG) neurons infected with an IE gene-deﬁcient HSV mutant,
d109, made several observations of note. d109 was generally more
transcriptionally active in TG neurons than in MRC5 cells (approxi-
mately 10-fold), and, in particular, the expression of LAT and other
genes within, or adjacent to, the terminal/internal repeat regions
was enhanced compared to the remainder of the genome in neu-
rons.38 These ﬁndings are consistent with our observations that
both JDNI5 and JDNI8 showed enhanced expression speciﬁcally in
DRGs, but not in HDFs, of the UbC-promoter driven mCherry
construct that is positioned at the deleted ICP4 locus in the terminal
repeat region of the genome. Our ﬁndings indicate that additional
deletion of vhs from the viral genome may further enhance the tran-
scriptional activity of this genomic location in neuronal cells. While
other repeat-associated genes were also expressed at higher levels in
DRGs than in HDFs, and than genes within the unique regions of
the viral genome in DRGs, vhs deletion did not further increase their
expression (g134.5) and in fact reduced ICP22 mRNA abundance.
The effect of vhs removal on transgene expression from the terminal
repeat-based LAT locus was also not dramatic. Expression in neurons
was modestly enhanced by vhs deletion, but this effect was not as
robust, nor was it maintained as long as at the ICP4 locus. In
HDFs, vhs removal led to reduced reporter gene expression from
the LAT locus and the already low levels of viral mRNAs appeared
to trend toward further reduction. Together, these observations sug-
gest distinctly separate utilities for the JDNI5 and JDNI8 vectors with
respect to the target cell for transgene expression; the ICP4 locus of
JDNI8 is favored for expression in neurons, while the LAT locus of
JDNI5 is preferable for expression in non-neuronal cell types.
The key event differentiating between JDNI5 and JDNI8 infection
would appear to be the initial introduction of vhs protein into non-
complementing cells as a component of the JDNI5 virion as (1) vhs
protein is synthesized and incorporated into infectious particles dur-
ing JDNI5, but not JDNI8 virus production by ICP4/ICP27-comple-
menting U2OS cells, and (2) de novo expression of viral genes iser 2017
www.moleculartherapy.orgextremely low in neurons infected with our vectors. However, we
observed expression differences between the two vectors out to at least
14 days in vitro and 1 month in vivo, long after the vhs protein is
degraded. As the incoming HSV genome is not epigenetically modi-
ﬁed and its subsequent silencing is controlled by cellular and viral fac-
tors upon entry into the host cell,39 it is conceivable that the initial
exposure of JDNI5-infected neurons to vhs indirectly affects the
epigenetic status of the mCherry locus, causing persistent downregu-
lation of the gene. While further studies are required to test this and
other possibilities, our current results indicate that vhs deletion may
be an attractive feature for highly defective HSV gene therapy vectors
for nervous system disorders.
MATERIALS AND METHODS
Cells
HDFs (PCS-201-010; ATCC) were cultured in DMEM (Lonza)
with 10% (v/v) fetal bovine serum (FBS; Sigma) and penicillin-strep-
tomycin (P/S). Vero-based ICP4/ICP27-complementing 7b cells
(Vero-7b)40 were cultured in DMEM with 5% FBS and P/S. Primary
fetal rDRGs were isolated and cultured as described previously.18
U2OS-ICP4/27 cells were grown in DMEM with 10% FBS and
P/S in the presence of puromycin (2 mg/mL) and blasticidin
(10 mg/mL), and U2OS-ICP4/27/Cre cells were maintained in
DMEM with 10% FBS and P/S in the presence of puromycin, blasti-
cidin, and hygromycin (200 mg/mL), as described previously.18
HSV-BAC Engineering
All BAC engineering was performed in E. coli strain GS178341 as
described.18 JDNI8 and JDNI8GFP BAC constructs were derived,
respectively, from JDNI5 and JDNI7GFP BACs.18 To delete the vhs
(UL41) coding sequence (GenBank JQ673480, positions 91,088–
92,557), the kanamycin selection marker, I-SceI-aphAI, was ampli-
ﬁed from pEPkan-S2 by PCR with primers 50-tatcaattgtggtcgttgttg
tggaaaagcaccagctggatgatgttgtacacgcgcgaaggatgacgacgataagtagggata-30
and 50-aatctgcagggcgcgccctacaaccaattaaccaattctgattag-30. The PCR
product was gel-puriﬁed and recombined with the vhs gene of
JDNI5 BAC or JDNI7GFP BAC, followed by removal of the aphA1
gene.
JDNI5R0 was constructed as follows: KOS-BAC DNA42 was digested
withDraI and PsiI to isolate a fragment containing the complete ICP0
gene. The ICP0 fragment was cloned into the pCR-Blunt vector using
the Zero Blunt PCR cloning kit (Thermo Fisher Scientiﬁc), creating
pCRBlunt-ICP0. The I-SceI-aphAI fragment was ampliﬁed by PCR
with primers (50-tatcaattgcgcaacacctgcccgctgtgcaacgccaagctggtgtac
ctgatagtgggaggatgacgacgataagtagggata-30 and 50-aatctgcagcaattgcta
caaccaattaaccaattctgattag-30), and the product was inserted into the
MfeI site of pCRBlunt-ICP0, creating pCRBlunt-ICP0-KAN. The
pCRBlunt-ICP0-KAN plasmid was digested with EcoRI and PstI,
and the isolated ICP0-KAN fragment was used for recombination
with JDNI5 BAC DNA. All HSV-BAC modiﬁcations were conﬁrmed
by ﬁeld inversion gel electrophoresis (FIGE) analysis of restriction
enzyme digests (FIGE mapper; Bio-Rad), PCR analysis, and targeted
DNA sequencing.Molecular TViruses
Production of infectious virus from BAC recombinants, Cre-medi-
ated BAC excision, and virus titration were performed as described
previously.18 JDNI viruses were grown in U2OS-ICP4/27 cells, the
KOS virus stock was produced on Vero cells, and QOZHG virus12
was grown in Vero-7b cells.
Virus Growth Curves
Duplicate wells of 4  105 U2OS-ICP4/27 cells were infected with
JDNI viruses at 1 gc/cell for 2 hr at 37C, treated with 0.1 M glycine
(pH 3.0) for 1 min to inactivate extracellular virus, and incubated
at 37C and 5% CO2. The supernatants were collected daily for
viral DNA extraction and titration by qPCR for the gD gene, as
described.18
Cytotoxicity Assay
Cell viability was measured essentially as described.43 Brieﬂy, dissoci-
ated rDRGs were plated in a 24-well plate (9  104 cells/well) and
infected with KOS or JDNI viruses at 3,000 gc/cell. Cell viability
was determined 5 days later by 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay.
qRT-PCR and Genomic qPCR
HDF and rDRG cells were plated in 24-well plates, and duplicate
wells were infected 24 hr later with JDNI viruses at MOIs of
25,000 gc/cell or 3,000 gc/cell, respectively. Total RNA was ex-
tracted, and RT was carried out by Cells-to-cDNA II Kit (Ambion).
Real-time PCR for each sample was performed in triplicate using
the StepOnePlus Real-Time PCR System (Applied Biosystems).
The data were normalized to viral gc in the same samples deter-
mined by qPCR for the gD gene or (Figure 2D) using separate
JDNI5 BAC DNA standard curves generated for each gene with
the gene-speciﬁc primer pairs used for cDNA qPCR to allow for
mRNA/gc comparisons between genes and across host cells. All
primers for qPCR were as previously reported.18 The gc titers of
virus stocks and nuclear viral DNA copy numbers were determined
as described.18
In Vivo Experiments
Under ketamine (90 mg/kg i.p.) and xylazine (13 mg/kg i.p.) anes-
thesia, 2 109 gc of JDNI vectors were inoculated into the right dorsal
hippocampus of male rats (Harlan Sprague Dawley, 300 g). The viral
vectors (JDNI5R0, JDNI5, and JDNI8) were injected by stereotactic
implantation of a borosilicate glass needle linked to a microperfusion
pump in a volume of 3 mL at a ﬂow rate of 200 nL/min. In order
to facilitate the needle entry into the brain tissue and to reduce
the mechanical damage, the needle tip had been laser-chamfered
(inner diameter at tip = 60 mm) using Leica Laser Microdissector
CTR6000 (Leica Microsystems). The stereotactic coordinates for
the hippocampal inoculation, based on the Paxinos atlas,44 were
2.1 mm lateral and 3 mm posterior to bregma, 3.5 mm deep from
dura. Experiments were performed at the University of Ferrara in
compliance with the university’s guidelines for the ethical treatment
of experimental animals.herapy: Methods & Clinical Development Vol. 6 September 2017 87
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Animals were anesthetized with pentobarbital at 7 or 30 days post-
virus injection and perfused with 0.1 M PBS followed by 4% parafor-
maldehyde. The brains were quickly removed and post-ﬁxed in 4%
paraformaldehyde for 1 hr, cryoprotected in 30% sucrose at 4C until
the tissue sank, and snap frozen in isopentane at 80C.
Immunofluorescence
20-mm coronal cryostat sections were cut at 20C on a freezing
microtome, rinsed in 0.1 M PBS for free-ﬂoating immunostaining,
and blocked with 10% normal goat serum/0.3% Triton X-100. Sec-
tions were then incubated overnight at 4C with primary antibodies
dissolved in blocking solution as follows: CD45 (Santa Cruz Biotech-
nology, sc-53047), 1:100; cleaved caspase-3 (Cell Signaling Technol-
ogy, 9664), 1:100; nitric oxide synthase-2 (Santa Cruz, sc-651),
1:100; mCherry (Thermo Fisher Scientiﬁc), 1:100; GFAP (Sigma),
1:200; O4 (Sigma), 1:100. After washing in PBS, sections were incu-
bated in blocking solution with 10 mM DAPI (Molecular Probes,
D3571) and either Alexa Fluor 488 goat anti-rabbit (Molecular
Probes, A11008, 1:1,000) or Alexa Fluor 488 goat anti-mouse (Molec-
ular Probes, A11029, 1:1,000) for 1 hr at room temperature.
Fluoro-Jade C Staining
Brain sections were mounted on frosted microscope slides (Thermo
Fisher Scientiﬁc) and pretreated for 5 min in 80% EtOH/1%
NaOH, 2 min in 70% EtOH, and 2 min in distilled water. Sections
were then incubated for 10 min in a 0.06% KMnO4 solution and
rinsed in distilled water for 3 min before incubation in a 0.0001%
solution of Fluoro-Jade C (Immunological Sciences, IS-0012) in
0.1% acetic acid for 10 min. After three washes in distilled water for
1 min, slides were dried, dehydrated with xylene, and coverslipped
with DPX mountant (Sigma) for microscopy.
Hippocampal Image Quantifications
Brain sections were imaged using a DMRA2 Leica microscope
(Leica Microsystems) and Hamamatsu C11440 camera. Confocal
images were captured using a HAL 100 camera (Zeiss) mounted
on a Zeiss LSM510 confocal microscope. Imaged mCherry expres-
sion was quantiﬁed with MetaMorph (Universal Imaging). The
entire hippocampus was selected as the region of interest (ROI).
mCherry-positive pixels were identiﬁed by thresholding at the
gray level corresponding to the mean plus the difference between
average and minimum. Using this approach, only those pixels that
were signiﬁcantly above background (i.e., mCherry-positive) were
selected. The percentage of mCherry-positive pixels in the hippo-
campus was calculated as the ratio of pixels above threshold to total
pixels in the ROI.
A similar procedure was employed for quantiﬁcation of FJC, CD45,
caspase-3, and NOS-2 signals. An outline was drawn around ﬁve
positive cells, and mean gray values were measured and averaged;
the resulting value was used to set the image threshold. Pixels above
the threshold were identiﬁed, as described above, and the number of
positive pixels was expressed as the percentage of total pixels.88 Molecular Therapy: Methods & Clinical Development Vol. 6 SeptembFor each injected animal, the number of mCherry-, FJC-, CD45-,
caspase-3-, and NOS-2-positive pixels was quantiﬁed from ﬁve regu-
larly interspaced sections spanning across the injection site (one of
every ﬁve 20-mm sections cut across the injection site, i.e., one per
100 mm with the third at the site of injection), and the average per
animal (three to ﬁve animals/group) was determined. These averages
were used for statistical analysis.
Statistical Analyses
Data from in vitro experiments are presented as the mean ± SD. Data
from in vivo experiments were analyzed by the Kruskal-Wallis test to
determine signiﬁcance.
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Figure S2. mCherry expression in J∆NI7GFP∆B- and J∆NI8GFP∆B-infected rDRGs. The images
document mCherry fluorescence in the same fields as GFP fluorescence shown in Figure 3D (7
dpi).
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Figure S1. mCherry protein levels in J∆NI5∆B- and J∆NI8∆B-infected rDRG cultures. Duplicate
wells of cells were infected with each virus as in Figure 2A (3000 gc/cell) and 4 different
microscopic fields of each well were photographed at 7 and 14 dpi. The percentage mCherry-
positive pixels in each field was determined from the number of pixels above threshold to total
pixels established by ImageJ analysis (Fiji, http://fiji.sc/). Data are presented relative to J∆NI5∆B-
infected cells at 7 dpi and represent averages ± SD of two independent experiments.
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Figure S3. J∆NI5R0 genome structure and activity. (A) HSV-BAC engineering was used to repair
the deleted ICP0 locus in the UL-flanking terminal repeat of J∆NI5. (B) J∆NI5R0 superinfection
enhances GFP fluorescence in J∆NI8GFP∆B-infected fibroblasts. HDFs in 96-well plates were
infected with J∆NI8GFP∆B at 25000 gc/cell and superinfected 6 days later with mock or J∆NI5R0
virus at 108 gc/well. GFP fluorescence was imaged 24 h after superinfection. (C) Relative GFP
mRNA levels in mock- and J∆NI5R0-superinfected cells. Following HDF infection and
superinfection as above, the cells were harvested 24 h after superinfection for mRNA and DNA
isolation. GFP mRNA levels measured by qRT-PCR were normalized to J∆NI8GFP∆B viral
genome copy numbers determined by qPCR for the CAG promoter. Averages ± SD of two
independent experiments.
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Figure S4. Neurons were the prevalent cell type expressing mCherry after J∆NI8∆B injection of
the hippocampus. Representative confocal images from coronal sections prepared from animals
killed 1 week after vector injection into the right hippocampus (4 animals/group). Note
overlapping signal in neuronal cell bodies (A, NeuroTrace) for all mCherry-expressing cells. No
overlap was observed with GFAP, a marker of astrocytes (B) or with O4, a marker of
oligodendrocytes (C). Horizontal bar, 100 μm.
